BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 31099645)

  • 1. Relapsed and Refractory Classical Hodgkin Lymphoma: Keeping Pace With Novel Agents and New Options for Salvage Therapy.
    Moskowitz AJ; Herrera AF; Beaven AW
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():477-486. PubMed ID: 31099645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Where Do the New Drugs Fit in for Relapsed/Refractory Hodgkin Lymphoma?
    Khan N; Moskowitz AJ
    Curr Hematol Malig Rep; 2017 Jun; 12(3):227-233. PubMed ID: 28488185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation.
    Taçyıldız N; Tanyıldız HG; Ünal E; Dinçaslan H; Asarcıklı F; Aksoy BA; Vatansever G; Yavuz G
    Turk J Pediatr; 2019; 61(5):671-676. PubMed ID: 32104998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naïve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP).
    Pavone V; Mele A; Carlino D; Specchia G; Gaudio F; Perrone T; Mazza P; Palazzo G; Guarini A; Loseto G; Eleonora P; Cascavilla N; Scalzulli P; Melpignano A; Quintana G; Di Renzo N; Tarantini G; Capalbo S
    Ann Hematol; 2018 Oct; 97(10):1817-1824. PubMed ID: 30054707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients.
    Zinzani PL; Pellegrini C; Cantonetti M; Re A; Pinto A; Pavone V; Rigacci L; Celli M; Broccoli A; Argnani L; Pulsoni A
    Oncologist; 2015 Dec; 20(12):1413-6. PubMed ID: 26500229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition?
    Othman T; Herrera A; Mei M
    Curr Hematol Malig Rep; 2021 Feb; 16(1):1-7. PubMed ID: 33409966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.
    Merli M; Ferrario A; Maffioli M; Olivares C; Stasia A; Arcaini L; Passamonti F
    Expert Rev Hematol; 2016 Aug; 9(8):767-80. PubMed ID: 27416486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Therapies in the Treatment of Hodgkin Lymphoma.
    Andrade-Gonzalez X; Ansell SM
    Curr Treat Options Oncol; 2021 Mar; 22(5):42. PubMed ID: 33755826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.
    LaCasce AS; Bociek RG; Sawas A; Caimi P; Agura E; Matous J; Ansell SM; Crosswell HE; Islas-Ohlmayer M; Behler C; Cheung E; Forero-Torres A; Vose J; O'Connor OA; Josephson N; Wang Y; Advani R
    Blood; 2018 Jul; 132(1):40-48. PubMed ID: 29703778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation.
    Milgrom SA; Jauhari S; Plastaras JP; Nieto Y; Dabaja BS; Pinnix CC; Smith GL; Allen PK; Lukens JN; Maity A; Oki Y; Fanale MA; Nasta SD
    Cancer; 2017 Apr; 123(8):1363-1371. PubMed ID: 27984652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma.
    Moskowitz AJ; Schöder H; Gavane S; Thoren KL; Fleisher M; Yahalom J; McCall SJ; Cadzin BR; Fox SY; Gerecitano J; Grewal R; Hamlin PA; Horwitz SM; Kumar A; Matasar M; Ni A; Noy A; Palomba ML; Perales MA; Portlock CS; Sauter C; Straus D; Younes A; Zelenetz AD; Moskowitz CH
    Blood; 2017 Nov; 130(20):2196-2203. PubMed ID: 28874350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma.
    Desai SH; Spinner MA; David K; Bachanova V; Goyal G; Kahl B; Dorritie K; Azzi J; Kenkre VP; Arai S; Chang C; Fusco B; Sumransub N; Hatic H; Saba R; Ibrahim U; Harris EI; Shah H; Murphy J; Ansell S; Jagadish D; Orellana-Noia V; Diefenbach C; Iyenger S; Rappazzo KC; Mishra R; Choi Y; Nowakowski GS; Advani RH; Micallef IN
    Am J Hematol; 2023 Mar; 98(3):464-471. PubMed ID: 36629030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score-matched analysis.
    Driessen J; de Wit F; Herrera AF; Zinzani PL; LaCasce AS; Cole PD; Moskowitz CH; García-Sanz R; Fuchs M; Müller H; Borchmann P; Santoro A; Schöder H; Zijlstra JM; Hutten BA; Moskowitz AJ; Kersten MJ
    Blood Adv; 2024 Jun; 8(11):2740-2752. PubMed ID: 38502227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective study.
    Bröckelmann PJ; Zagadailov EA; Corman SL; Chirikov V; Johnson C; Macahilig C; Seal B; Dalal MR; Illidge T
    Eur J Haematol; 2017 Dec; 99(6):553-558. PubMed ID: 28949403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma.
    Voorhees TJ; Beaven AW
    Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33050054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Salvage Therapy Options for Initial Treatment of Relapsed/Refractory Classical Hodgkin's Lymphoma: So Many Options, How to Choose?
    Takiar R; Karimi Y
    Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating Hodgkin lymphoma in the new millennium: Relapsed and refractory disease.
    LaCasce AS
    Hematol Oncol; 2019 Jun; 37 Suppl 1():87-91. PubMed ID: 31187532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma.
    Pinczés LI; Szabó R; Illés Á; Földeák D; Piukovics K; Szomor Á; Gopcsa L; Miltényi Z
    Ann Hematol; 2020 Oct; 99(10):2385-2392. PubMed ID: 32748163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential survival benefit for patients receiving autologous hematopoietic stem cell transplantation after checkpoint inhibitors for relapsed/refractory Hodgkin lymphoma: A real-life experience.
    Casadei B; Argnani L; Morigi A; Lolli G; Broccoli A; Pellegrini C; Nanni L; Stefoni V; Coppola PE; Carella M; Cavo M; Zinzani PL
    Hematol Oncol; 2020 Dec; 38(5):737-741. PubMed ID: 32905626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation.
    Shah GL; Yahalom J; Matasar MJ; Verwys SL; Goldman DA; Bantilan KS; Zhang Z; McCall SJ; Moskowitz AJ; Moskowitz CH
    Br J Haematol; 2016 Nov; 175(3):440-447. PubMed ID: 27377168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.